Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Ocera Therapeutics gets $35.5mm through its Series C

Executive Summary

Ocera Therapeutics (gastrointestinal and liver disease compounds) has raised $35.5mm through the closing of its Series C venture round. Lead investor Montagu Newhall Associates was joined by other new backers InterWest Partners, AgeChem Venture Fund, Cross Creek Capital (an affiliate of Wasatch Advisors), FinTech, and CDIB BioScience. Current shareholders Domain Associates, Sofinnova Ventures, and Thomas, McNerney & Partners also participated. A representative from InterWest Partners will take a seat on the company's board.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies